Current studentsExisting staffContact us
 

Toward stable genetic engineering of human O-glycosylation in plants

Simple item page
dc.contributor.authorYang, Z.
dc.contributor.authorBennett, E.
dc.contributor.authorJørgensen, B.
dc.contributor.authorDrew, D.
dc.contributor.authorArigi, E.
dc.contributor.authorMandel, U.
dc.contributor.authorUlvskov, P.
dc.contributor.authorLevery, S.
dc.contributor.authorClausen, H.
dc.contributor.authorPetersen, B.
dc.date.issued2012
dc.description.abstractGlycosylation is the most abundant and complex posttranslational modification to be considered for recombinant production of therapeutic proteins. Mucin-type (N-acetylgalactosamine [GalNAc]-type) O-glycosylation is found in eumetazoan cells but absent in plants and yeast, making these cell types an obvious choice for de novo engineering of this O-glycosylation pathway. We previously showed that transient implementation of O-glycosylation capacity in plants requires introduction of the synthesis of the donor substrate UDP-GalNAc and one or more polypeptide GalNAc-transferases for incorporating GalNAc residues into proteins. Here, we have stably engineered O-glycosylation capacity in two plant cell systems, soil-grown Arabidopsis (Arabidopsis thaliana) and tobacco (Nicotiana tabacum) Bright Yellow-2 suspension culture cells. Efficient GalNAc O-glycosylation of two stably coexpressed substrate O-glycoproteins was obtained, but a high degree of proline hydroxylation and hydroxyproline-linked arabinosides, on a mucin (MUC1)-derived substrate, was also observed. Addition of the prolyl 4-hydroxylase inhibitor 2,2-dipyridyl, however, effectively suppressed proline hydroxylation and arabinosylation of MUC1 in Bright Yellow-2 cells. In summary, stably engineered mammalian type O-glycosylation was established in transgenic plants, demonstrating that plants may serve as host cells for the production of recombinant O-glycoproteins. However, the present stable implementation further strengthens the notion that elimination of endogenous posttranslational modifications may be needed for the production of protein therapeutics.
dc.description.statementofresponsibilityZhang Yang, Eric P. Bennett, Bodil Jørgensen, Damian P. Drew, Emma Arigi, Ulla Mandel, Peter Ulvskov, Steven B. Levery, Henrik Clausen, and Bent L. Petersen
dc.identifier.citationPlant Physiology, 2012; 160(1):450-463
dc.identifier.doi10.1104/pp.112.198200
dc.identifier.issn0032-0889
dc.identifier.issn1532-2548
dc.identifier.urihttp://hdl.handle.net/2440/95813
dc.language.isoen
dc.publisherAmerican Society of Plant Biologists
dc.rights© 2012 American Society of Plant Biologists. All Rights Reserved.
dc.source.urihttps://doi.org/10.1104/pp.112.198200
dc.subjectAcetylgalactosamine
dc.titleToward stable genetic engineering of human O-glycosylation in plants
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Agriculture, Food and Wine publications